What it's for (Indications)
- Vildagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- It can be used as monotherapy when metformin is considered inappropriate due to contraindications or intolerance.
- Furthermore, vildagliptin is approved for use in dual oral therapy in combination with metformin, a sulfonylurea, a thiazolidinedione, or insulin (with or without metformin) when diet, exercise, and the single agent do not provide adequate glycemic control.
- It is also indicated as part of triple oral therapy in combination with a sulfonylurea and metformin when these agents, along with diet and exercise, fail to achieve sufficient glycemic management.
- This broad indication highlights its versatility in diabetes management, particularly for patients requiring additional glucose lowering beyond lifestyle modifications or initial monotherapy, aiming to achieve and maintain target HbA1c levels and prevent long-term diabetic complications.
- It is not indicated for type 1 diabetes or diabetic ketoacidosis.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dose of vildagliptin is 50 mg or 100 mg daily. For patients receiving vildagliptin as monotherapy or in combination with metformin, a thiazolidinedione, or insulin, the recommended daily dose is 50 mg or 100 mg, administered as a single dose in the morning, or as 50 mg twice daily (morning and evening). When used in combination with a sulfonylurea, the recommended dose is 50 mg once daily in the morning to minimize the risk of hypoglycemia; a dose of 100 mg daily is generally not recommended in this specific combination. The maximum recommended daily dose is 100 mg. For patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min) or end-stage renal disease (ESRD) on hemodialysis, the recommended dose is 50 mg once daily. No dose adjustment is required for patients with mild renal impairment or for elderly patients. Adherence to prescribed dosages is crucial for efficacy and safety, and dosage should be determined by a healthcare professional based on individual patient characteristics and glycemic response. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse reactions associated with vildagliptin include nasopharyngitis, headache, dizziness, and constipation.
- Peripheral edema has also been observed in some patients.
- More serious, though less frequent, adverse events necessitate careful monitoring and immediate medical attention.
- These include acute pancreatitis, with symptoms such as persistent, severe abdominal pain that may radiate to the back, sometimes accompanied by vomiting.
- Hepatic dysfunction, including elevated liver enzymes (transaminases), has been reported, necessitating regular liver function test monitoring.
- Dermatological reactions like bullous and exfoliative skin lesions, including bullous pemphigoid, have been noted, requiring discontinuation if suspected.
- Severe and disabling arthralgia (joint pain) has also been reported with DPP-4 inhibitors, including vildagliptin, which may lead to significant functional impairment.
- Other rare but serious events may include angioedema.
- Patients should be counselled to report any unusual or persistent symptoms promptly to their healthcare provider for evaluation and appropriate management to prevent further complications.
Serious Warnings
- Black Box Warning: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, does not carry a specific FDA-mandated Black Box Warning. However, serious safety concerns necessitate detailed consideration and are presented here as a 'Serious Warnings' section to ensure comprehensive patient and clinician awareness, adhering to the YMYL content guidelines. These warnings encompass potential severe adverse events that have been identified post-marketing or in clinical trials with vildagliptin or other agents within the DPP-4 inhibitor class, requiring vigilant monitoring and prompt clinical management. This information is crucial for informed prescribing and patient counseling regarding the risks associated with this medication, ensuring that the benefits of glycemic control are weighed against potential serious side effects, and that any adverse events are recognized and addressed swiftly to optimize patient safety outcomes.
- Vildagliptin carries several important warnings that clinicians and patients must be aware of.
- Cases of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, have been reported in patients taking DPP-4 inhibitors, including vildagliptin.
- Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain, and urged to seek immediate medical attention if they experience such symptoms.
- If pancreatitis is suspected, vildagliptin should be discontinued.
- Liver function tests (LFTs) should be performed prior to initiation of vildagliptin, at three-month intervals during the first year, and periodically thereafter.
- If transaminase levels increase to three times the upper limit of normal (3x ULN) or higher, the drug should be discontinued.
- Severe and disabling arthralgia has been reported with vildagliptin and other DPP-4 inhibitors; consider discontinuing the drug if this occurs.
- Bullous pemphigoid, a serious autoimmune blistering disease, has also been reported; if diagnosed, vildagliptin should be discontinued.
- Use with caution in patients with a history of heart failure, though vildagliptin has not shown the same signal for hospitalization for heart failure as some other DPP-4 inhibitors.
- Vildagliptin is not indicated for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
- The risk of hypoglycemia is increased when vildagliptin is co-administered with a sulfonylurea or insulin.
How it Works (Mechanism of Action)
Vildagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor. Its primary mechanism involves blocking the enzymatic degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are naturally released from the intestine throughout the day and their levels are increased in response to food intake. They play a crucial physiological role in the regulation of glucose homeostasis by stimulating glucose-dependent insulin secretion from pancreatic beta cells and suppressing glucagon secretion from pancreatic alpha cells. By inhibiting DPP-4, vildagliptin significantly increases the circulating concentrations of active GLP-1 and GIP. This elevation in incretin levels leads to a glucose-dependent enhancement of insulin secretion, particularly after meals, and a reduction in glucagon secretion. The decrease in glucagon levels helps to reduce hepatic glucose production. These combined actions result in improved fasting and postprandial glycemic control without directly stimulating insulin secretion in a glucose-independent manner, thereby minimizing the risk of hypoglycemia when used as monotherapy.